@article{tracy_goggs_brooks_lynch_2022, title={Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases}, volume={4}, ISSN={["1476-4431"]}, DOI={10.1111/vec.13199}, abstractNote={Abstract Objective To describe a population of sick dogs administered rivaroxaban monitored with a rivaroxaban‐calibrated anti‐Xa activity assay (aXa). Design Descriptive retrospective study. Setting Two veterinary teaching hospitals. Animals Client‐owned dogs administered rivaroxaban and monitored with aXa from January 2018 to January 2020 were eligible for study. Interventions None. Measurements and Main Results Medical records were reviewed and 19 dogs with a variety of underlying disease processes were identified. Rivaroxaban was administered to 12 of 19 dogs (63%) with confirmed thrombosis, 4 of 19 dogs (21%) with a strong clinical suspicion of thrombosis, and in 3 of 19 dogs (16%) with no current evidence of thrombosis. The median rivaroxaban dose administered was 0.96 mg/kg/day (0.62–1.58 mg/kg/day), with 15 of 19 dogs (79%) receiving rivaroxaban once daily. Clopidogrel was concurrently administered to 11 of 19 dogs (58%). Complete or partial thrombus resolution was identified in 5 of 12 (42%) and 3 of 12 (25%) dogs, respectively. Rivaroxaban appeared safe, with only 1 of 19 dogs (5%), concurrently administered clopidogrel, developing evidence of mild hematuria. Posttreatment monitoring revealed that 8 of 19 dogs (42%) had aXa below the target (aXa range of 150–250 ng/ml associated with effective treatment and prevention of venous thrombosis in people). The remaining 3 to 19 dogs (16%) achieved this range, and 8 of 19 dogs (42%) exceeded the range. No significant relationship between the initial rivaroxaban dose administered and the corresponding aXa result was identified. There were also no significant differences in baseline clinicopathological variables in dogs in which aXa fell within or outside this range. Conclusions aXa was most commonly measured in dogs receiving rivaroxaban with confirmed or suspected thrombosis. Dogs in this study received a range of rivaroxaban dosages and attained variable aXa values that were not directly correlated with dosage.}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Tracy, Alyxandra L. and Goggs, Robert and Brooks, Marjory B. and Lynch, Alex M.}, year={2022}, month={Apr} }
 @article{tracy_lynch_messenger_vaden_vigani_2021, title={Use of extracorporeal therapy in a dog with heatstroke}, volume={12}, ISSN={["1476-4431"]}, DOI={10.1111/vec.13169}, abstractNote={To describe the use of extracorporeal therapy (ECT) in the management of a dog with complications stemming from heatstroke.A 3-year-old intact male Rhodesian Ridgeback was presented for heat-related illness following strenuous exercise. Despite intensive supportive care, the dog developed progressive and refractory hyperkalemia, hypoglycemia, neurologic dysfunction, acute kidney injury (AKI), and pulmonary dysfunction. Four ECT sessions were performed in this dog, consisting of 4 intermittent hemodialysis (HD) sessions, the first 2 of which concurrently utilized hemoperfusion with a cytokine adsorption filter. Interleukin-6 (IL-6), IL-8, IL-10, and monocyte chemoattractant protein-1 were detected in samples collected during the first ECT session. Despite an initial decrease in their concentration, the concentrations of these cytokines ultimately rose over the course of the ECT session. Rapid and sustained glycemic and electrolyte control were achieved after the first ECT session, although AKI and muscle injury persisted. The dog survived to discharge and was nonazotemic 3 months following initial management.Heatstroke is a common, potentially catastrophic, occurrence in dogs. To the authors' knowledge, this represents the first clinical use of ECT consisting of HD and cytokine adsorption in the management of severe heat-related illness in a dog. The use of ECT for the management of complications from severe heatstroke in dogs warrants further investigation.}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Tracy, Alyx and Lynch, Alex and Messenger, Kristen and Vaden, Shelly and Vigani, Alessio}, year={2021}, month={Dec} }